BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19235235)

  • 1. Device selection for percutaneous coronary intervention: The case is still open.
    Lemos PA
    Catheter Cardiovasc Interv; 2009 Mar; 73(4):466. PubMed ID: 19235235
    [No Abstract]   [Full Text] [Related]  

  • 2. Outcome of patients treated by a novel thin-strut cobalt-chromium stent in the drug-eluting stent era: Results of the SKICE (Skylor in real world practice) registry.
    Burzotta F; Trani C; Todaro D; Mazzari MA; Porto I; De Vita M; Brugaletta S; Coroleu SF; Niccoli G; Leone AM; Giammarinaro M; Mongiardo R; Schiavoni G; Crea F
    Catheter Cardiovasc Interv; 2009 Mar; 73(4):457-65. PubMed ID: 19229977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous coronary intervention in nonagenarians: age before beauty?
    Bhatt DL
    Catheter Cardiovasc Interv; 2008 Mar; 71(4):531-2. PubMed ID: 18307234
    [No Abstract]   [Full Text] [Related]  

  • 4. Vessel healing: checking in-vivo results for better treatment.
    Manfrini O
    J Cardiovasc Med (Hagerstown); 2011 May; 12(5):311-3. PubMed ID: 21451333
    [No Abstract]   [Full Text] [Related]  

  • 5. When are two stents needed? Which technique is the best? How to perform?
    Latib A; Moussa I; Sheiban I; Colombo A
    EuroIntervention; 2010 Dec; 6 Suppl J():J81-7. PubMed ID: 21930497
    [No Abstract]   [Full Text] [Related]  

  • 6. The AUTAX (Austrian Multivessel TAXUS-Stent) registry: another useful registry on stented angioplasty for multivessel disease?
    Wijns W
    JACC Cardiovasc Interv; 2009 Aug; 2(8):728-30. PubMed ID: 19695540
    [No Abstract]   [Full Text] [Related]  

  • 7. Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion.
    Tcheng JE; Zidar DA
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1266-8. PubMed ID: 20129554
    [No Abstract]   [Full Text] [Related]  

  • 8. Let it be, let it be.
    Butman SM
    Catheter Cardiovasc Interv; 2009 Jun; 73(7):898. PubMed ID: 19455656
    [No Abstract]   [Full Text] [Related]  

  • 9. The Petal dedicated bifurcation stent.
    Ormiston JA; De Vroey F; Webster MW; Kandzari DE
    EuroIntervention; 2010 Dec; 6 Suppl J():J139-42. PubMed ID: 21930479
    [No Abstract]   [Full Text] [Related]  

  • 10. Baseline fractional flow reserve and stent diameter predict event rates after stenting: a further step, but still much to learn.
    Leesar MA
    JACC Cardiovasc Interv; 2009 Apr; 2(4):364-5. PubMed ID: 19463451
    [No Abstract]   [Full Text] [Related]  

  • 11. Polymeric stents: degradable but strong.
    Lemos PA
    Catheter Cardiovasc Interv; 2007 Oct; 70(4):524. PubMed ID: 17896407
    [No Abstract]   [Full Text] [Related]  

  • 12. Bifurcation disease: what do we know, what should we do?
    Latib A; Colombo A
    JACC Cardiovasc Interv; 2008 Jun; 1(3):218-26. PubMed ID: 19463303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evidence-based approach to the use of rotational and directional coronary atherectomy in the era of drug-eluting stents: when does it make sense?
    Tran T; Brown M; Lasala J
    Catheter Cardiovasc Interv; 2008 Nov; 72(5):650-62. PubMed ID: 18942126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Nile concept.
    Fajadet J
    EuroIntervention; 2010 Dec; 6 Suppl J():J135-8. PubMed ID: 21930478
    [No Abstract]   [Full Text] [Related]  

  • 15. The "mini-crush" technique for managing bifurcation lesions.
    Kornowski R
    Catheter Cardiovasc Interv; 2009 Jul; 74(1):85-7. PubMed ID: 19530202
    [No Abstract]   [Full Text] [Related]  

  • 16. Stent expansion as a mechanical parameter to predict late stent patency: back to the basics.
    Honda Y; Fitzgerald PJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1276-8. PubMed ID: 20129556
    [No Abstract]   [Full Text] [Related]  

  • 17. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.
    Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting or bare-metal stents in subjects over 75 years of age: what is the best therapeutic strategy? Data from 460 consecutive patients with 1-year outcome.
    Ouldzein H; Roncalli J; Zouaoui W; Bongard V; Boudou N; Dumonteil N; Lhermusier T; Elbaz M; Puel J; CarriƩ D
    Cardiovasc Revasc Med; 2009; 10(2):94-102. PubMed ID: 19327671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular restoration therapy: what should the clinical and angiographic measures for success be?
    Khattab AA; Windecker S
    EuroIntervention; 2009 Dec; 5 Suppl F():F49-53. PubMed ID: 22100676
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravascular ultrasound optimization of drug-eluting stents: still not enough data.
    Leesar MA
    Catheter Cardiovasc Interv; 2010 Mar; 75(4):584-5. PubMed ID: 20333656
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.